Skip to Main Content

Advertisement

Issue Archive

Table of Contents

CLINICAL TRIALS AND OBSERVATIONS

THROMBOSIS AND HEMOSTASIS

MYELOID NEOPLASIA

TRANSPLANTATION

PLATELETS AND THROMBOPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

THROMBOSIS AND HEMOSTASIS

Red Cells, Iron, and Erythropoiesis

Lymphoid Neoplasia

Red Cells, Iron, and Erythropoiesis

MYELOID NEOPLASIA

THROMBOSIS AND HEMOSTASIS

Lymphoid Neoplasia

MYELOID NEOPLASIA

CLINICAL TRIALS AND OBSERVATIONS

The introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib revolutionized the treatment of chronic lymphocytic leukemia. However, because inefficacy or intolerable side effects, some patients do not benefit. Acalabrutinib is a covalent BTK inhibitor with greater selectivity than ibrutinib. Byrd and colleagues explored acalabrutinib in patients refractory to or intolerant of ibrutinib, finding exciting evidence for efficacy and tolerability.

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement